Topical rVA576 for Treatment of Atopic Keratoconjunctivitis

NCT04037891 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
12
Enrollment
INDUSTRY
Sponsor class

Stopped The trial has terminated early due to the disruptions caused by the ongoing COVID-19 pandemic. The decision was not related to any efficacy, safety or clinical concerns regarding rVA576.

Conditions

Interventions

Sponsor

AKARI Therapeutics